We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Register to vote Register by 18 June to vote in the General Election on 4 July.
The MHRA has published advice for patients and healthcare professionals
Topical steroid products are safe and highly effective treatments for the management of a wide range of inflammatory skin diseases but have important risks, especially with prolonged use at high potency. In the coming months, as a result of regulatory...
Advice and guidance on the health needs of migrant patients for healthcare practitioners.
Information on carrying medicine containing controlled drugs for individual travellers entering or leaving the UK.
Change your protocol, update your authorisation, report safety issues, submit safety updates and complete your end-of-trial study report.
As a vet or pharmacist, you must follow legal requirements when working with controlled drugs in veterinary medicine.
Information for companies on the import and export of controlled drugs to and from the UK.
Information for patients, healthcare professionals and developers of new medicines
Healthcare professionals prescribing montelukast should be alert to the risk of neuropsychiatric reactions in all patients including children and adolescents. Reported neuropsychiatric reactions include sleep disorders, hallucinations, anxiety and depression, as well as changes in behaviour and mood. Healthcare professionals...
A new pathway supporting innovative approaches to the safe, timely and efficient development of medicines to improve patient access.
Study assessed the effects using a two-period single-sequence design.
How the MHRA makes decisions on when a product is a medical device (borderline products), and which risk class should apply to a medical device.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).